WaveMan
WaveMan · Company
ADAPY · Adaptimmune Therapeutics Plc
> Search tickers & screens ⌘K
LIVE
← All companies

ADAPY Adaptimmune Therapeutics (ADAPY) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001621227
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Adaptimmune Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Adaptimmune Therapeutics PLC in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Rawcliffe Adrian
Chief Executive Officer
SELL
2021-09-01 SEC
2,782
$14.5K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 90.6% of the 3,070 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Chief Executive Officer Rawcliffe Adrian sold about $14.5K of ADAPY on Sep 1, 2021, the largest insider sale at the company on our record.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+195.3% year over year
more than 89% of Pharma & Biotech
Margin
-39.8% net margin
more than 52% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.5% of the float short (float per yahoo 2026-10-26) · 2.1 days to cover · settled 2026-09-30
below 89% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ADAPY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns ADAPY: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in ADAPY

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ADAPY planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Adrian Rawcliffe
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$2.8M
$1.2M
$1.2M
-34%
+15%
2022
$3.4M
-$47.0K
$1.7M
+22%
+11%
2021
$4.2M
$2.0M
$1.8M
+212%
+25%
2020
$2.7M
$5.9M
$1.3M
+349%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ADAPY financials

Revenue growth
+195.3%
XBRL, annual
Net margin
-39.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$65.1M
four quarters, 2024-07-01 to 2025-06-30
Net margin, TTM
-260.8%
net income over revenue, 2024-07-01 to 2025-06-30
Free cash flow, TTM
-$191.7M
operating cash flow minus capex, 2024-07-01 to 2025-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-7.40x
TTM operating cash flow over long-term debt only, 2025-06-30
Return on equity
-1,341%
TTM net income over average of 2024-06-30 and 2025-06-30
Return on assets
-75.1%
TTM net income over average of 2024-06-30 and 2025-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-103.0%
operating income (EBIT proxy) over average of 2024-06-30 and 2025-06-30 minus current liabilities
P/E, trailing
n/a
no close on file at or before the as-of date
Enterprise value
n/a
no close on file at or before the as-of date
FCF yield
n/a
no close on file at or before the as-of date
PEG, trailing
n/a
no close on file at or before the as-of date
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122023-122022-122021-12
Revenue$178.0M$60.3M$27.1M$6.1M
Operating income-$68.8M-$139.7M-$164.0M-$162.2M
Net income-$70.8M-$113.9M-$165.5M-$158.1M
EPS (diluted)-0.05-0.09-0.17-0.17
Operating cash flow-$73.2M-$140.9M-$141.8M$10.7M
Cash$91.1M$144.0M$108.0M$149.9M
Long-term debt$50.2Mn/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-27

ADAPY Stock Sonar score 4/7 axes

Find similar shapesCompare

ADAPY ranks highest on risk and compliance (87th percentile) and growth (61st), and lowest on profitability (20th), among Pharma & Biotech peers.

Profitability
20
Inputs
  • Return on equity-1341% · 3 pct, sector of 545
  • Return on assets-75.1% · 32 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-103.0% · 24 pct, sector of 576
Financial health
25
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-7.40x · 25 pct, sector of 371
Growth
61
Inputs
  • Revenue growth, YoY+195.3% · 89 pct, sector of 505
  • Backlog growth, YoY-21.4% · 33 pct, sector of 40
Risk and compliance
87
Inputs
  • Short interest, % of float+0.5% · 87 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies